Wednesday, July 8, 2026

Patent intelligence · US

US 9861617

Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use

granted A61KA61K31/4245A61K31/4439A61K31/454
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 11
Applicant portfolio 149
Patent details — US 9861617
Jurisdiction
US
Status
granted
Grant date
Jan 9, 2018
Expiration
Jan 4, 2038
Claims
21
CPC classes
A61K, A61K31/4245, A61K31/4439, A61K31/454
View on Google Patents ↗

Quick answer

US 9861617 (Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Jan 9, 2018. Expires Jan 4, 2038 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
21
CPC classes
A61K, A61K31/4245, A61K31/4439, A61K31/454, A61K31/4545, A61K31/5377

More from PTC THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 21, 2045

    granted
  2. US 12384789

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  3. US 12384797

    Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  4. US 12281083

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  5. US 12139499

    Heteroaryl compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Nov 7, 2044

    granted
  6. US 12103926

    Compounds for treating huntington's disease

    PTC THERAPEUTICS, INC. · Expires Sep 26, 2044

    granted
  7. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. · Expires Jun 27, 2044

    granted
  8. US 11938101

    Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Expires Mar 21, 2044

    granted

Frequently asked questions

What is US patent 9861617?

US 9861617 (Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Jan 9, 2018. Expires Jan 4, 2038 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9861617?

PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.

When does US 9861617 expire?

Our index shows an expiration date of Jan 4, 2038 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.